Ka ọ dị ugbu a, ụlọ ọrụ ahụ arụchaala ọrụ dị mkpa nke nyocha ụlọ ọrụ Phase II na nkwadebe nke nnwale na-adọkpụ ọrịa Phase III nke ntụtụ Albenatide. Dabere na nsonaazụ nnwale ụlọ ọgwụ nke mbụ na nyocha nnwale ụlọ ọgwụ chọrọ nke Albenatide, jikọtara ya na ọnọdụ ụlọ ọrụ ahụ n'ezie, ụlọ ọrụ ahụ kwenyere na ọ nweelarị ọnọdụ ịmalite ọnwụnwa ụlọ ọgwụ III wee kpebie ịmalite ikpe nke ụlọ ọgwụ III. .
Albenatide bụ ọgwụ klas 1.1 maka ọgwụgwọ nke ọrịa shuga II. Ọ bụ nkwadebe agonist GLP-1 na-anabata ịgwọ ọrịa nwere ike ịgbanye ya otu ugboro n'izu, nke na - eme ka nnabata onye ọrịa ghara ị greatlyụ ọgwụ ike.

Companylọ ọrụ ahụ mere nnwale nke ịgba ọgwụ mgbochi nke Albenatide na atlọ Ọgwụ nke Mahadum Jilin, yana nnwale ahụike nke Albenatide injection II II n'ụlọ ọgwụ 28 gụnyere ụlọ ọgwụ Peking University People’s Hospital. Mgbe emechara nyocha ụlọ nyocha nke Phase II nke Albenatide na June 7, 2019, ụlọ ọrụ ahụ mere nyocha nyocha na nchịkọta nke nyocha nyocha dị mkpa. Ruo ugbu a, ụlọ ọrụ ahụ emechaala nyocha ụlọ ọgwụ II nke metụtara ntụtụ Albenatide. Nsonaazụ nnwale nke ụlọ nyocha nke II nke Albenatide gbara gosiri na ebumnuche ebumnuche nke ụlọ ọrụ II ruru.